Redefining Cannabinoid Biology in Obesity with Semaglutide-Like Weight Loss and Enhanced Efficacy Through Combination Therapy with ART27.13; a Peripherally Restricted CB1/CB2 Agonist
1:30 pm - Thursday 10th December 2026
- Demonstrating semaglutide-like efficacy with once-daily oral, cannabinoid agonist ART27.13, achieving ~20% weight loss and significant fat mass reduction in a nonclinical obesity model
- Enhancing weight-loss outcomes through combination therapy, with ART27.13 and semaglutide together delivering ~40% weight loss, double that achieved by either treatment alone
- Unlocking a novel peripheral cannabinoid-based approach to metabolic regulation, improving body composition and metabolic health while showing obesity-specific effects
